The ASTRUM-005 trial (Cheng 2022) used PD-L1 expression levels (negative: tumor proportion score (TPS) < 1%, positive: TPS ≥ 1%, or not evaluable/unavailable) as a stratification factor, which can help us understand the prediction of PD-L1 value. Here, CD274 is linked to neoplasm.